Theoretically that's possible. Without AR it shouldn't be possible to continue balding. However, my >6 years of experience in combating hair loss tells me that this drug is nothing to be excited about yet. There are still many, many unknowns.
For instance, aside from ASC-J9 (dimethylcurcumin), AR degraders have not been used against Androgenetic Alopecia thus far. ASC-J9 effect was marginal and poor, but it was not a very good product in the first place.
There was another recently discovered AR degrader (very strong) called ARD-69:
In fact, the mechanisms are very similar to this Kintor product:
"
ARD-69 is a potent proteolysis-targeting chimera (PROTAC) degrader of the androgen receptor (AR) ... It contains an AR antagonist (reported in [
1]) that binds the AR, joined by a small linker molecule to a second ligand (in this case a VHL ligand) that
engages the E3 ubiquitin ligase system
via Cullin-2.
"
GT20029 is an AR degrader that degrades the AR protein. The mechanism of action of GT20029 is to recruit the
AR protein to the E3 ubiquitin ligase for degradation."
I wonder if Kintor perhaps bought out the rights to ARD-69 and whether it is the same thing. Haven't looked that in-depth into it.
Either way if you look at the molecular structure of ARD you notice that this molecule is much more complex than a typical anti-androgen, although once the linker chain breaks you are still left with a sort of typical AA structure floating around. I guess it will depend on how exactly these drugs are metabolized but unless it completely loses its affinity for the AR (and doesn't fall apart into small molecules which have their own AR affinity) once it hits the bloodstream, then there is still the potential for systemic side effects.